The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

IL-15 enhances the growth and survival of GPC3 CAR T cells, improving their ability to target and fight solid tumors Study: Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.

CAR T cells have shown limited efficacy in patients with solid cancers, despite dramatic success in some hematologic malignancies. Preclinical studies showed that the addition of IL-15, which helps T ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

The concept of CAR T-cells had been introduced by the immunologist Zelig Eshhar, PhD, about a decade earlier, and impatience was growing in the 10-15 labs around the world that were seeking to get ...

Non-Hodgkin lymphomas either begin in B cells or T cells — T-cell lymphomas account for less than 15 percent of all non-Hodgkin lymphomas. It mainly affects the skin — though they’re not ...

And stepping back you realize that we have been driving these CAR-T cells with the same basic design for the last 15 years," said Kohler. "When we began this project, we wanted to understand why ...

In recent years, CAR-T cell immunotherapy (using chimeric antigen receptors) has revolutionized the fight against cancer. In combination with other tools (chemotherapy, radiotherapy), this new ...

You can reach Angus on Signal at angus.08. To create one of the most advanced immunotherapies in cancer, CAR-T cell therapies, scientists engineer immune T cells to carry a synthetic protein on ...

Nineteen children with relapsed or refractory neuroblastoma were treated with CAR T cells engineered to target GD2 ... five were disease free at their last follow-up between 10-15 years after infusion ...

The team, which published its findings in an article titled, “Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers,” in Nature, tested chimeric antigen receptor (CAR ...